3
Participants
Start Date
August 7, 2017
Primary Completion Date
June 30, 2019
Study Completion Date
July 1, 2019
AvidinOX
"AvidinOX vial containing 22.5 mg AvidinOX~\+ vials containing 10 ml of water for injection (WFI) for the reconstitution in a clear solution with an AvidinOX concentration of 3 mg/ml. One Intralesion administration of a volume of reconstituted AvidinOX equal to about 15 % of the estimated lesion volume"
177Lu-ST2210
177Lu-ST2210 dose starting at 7.5 Gigabequerel (GBq) ±10%with escalation steps of 2.5 GBq up to 15 GBq ±10%, approximately 1 mg ST2210
177Lu-ST2210
Second dose of 177Lu-ST2210 dose (14 days after the first dose) starting at 7.5 Gigabequerel (GBq) ±10%with escalation steps of 2.5 GBq up to 15 GBq ±10%, approximately 1 mg ST2210
Dep. of Investigational Cancer Therapeutics - U. T. M. D. Anderson Cancer Center, Houston
Lead Sponsor
Alfasigma S.p.A.
INDUSTRY